Figure 3From: Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain Cost of treatments and overall survival (treatment cycles). MDS = myelodysplastic syndrome; AML = acute myeloid leukaemia; AZA = Azacitidine; BSC = best supportive care; LDC = low dose chemotherapy.Back to article page